22:40 , Sep 13, 2018 |  BC Week In Review  |  Clinical News

BMS's IPF therapy discontinued after Phase II safety signal

Data published in Chest showed that a twice-daily 600 mg dose of BMS-986020 from Bristol-Myers Squibb Co. (NYSE:BMY) significantly slowed the rate of decline in forced vital capacity (FVC) vs. placebo in the Phase II...
13:46 , Apr 11, 2017 |  BC Extra  |  Financial News

NASH newco Cirius raises $40M in series A

Liver company Cirius Therapeutics Inc. (Kalamazoo, Mich.) raised $40 million in a series A round led by Frazier Healthcare Partners and Novo A/S (Hellerup, Denmark). New investors Adams Street Partners and Renaissance Venture Capital Fund...
03:51 , Nov 19, 2016 |  BioCentury  |  Strategy

Adding on in fibrosis

Bristol-Myers Squibb Co. ’s deal to license worldwide rights to Nitto Denko Corp .’s antifibrotic siRNA therapy gives the pharma one of industry’s broadest fibrosis pipelines - and the ability to test multiple combinations. BMS...
01:37 , Feb 18, 2015 |  BC Extra  |  Financial News

Laguna raises $30M in B round

Laguna Pharmaceuticals Inc. (La Jolla, Calif.) raised $30 million in a series B round led by new investors Versant Ventures and Frazier Healthcare. New investor BioMed Ventures and existing investor Sante Ventures also participated. Formerly...
08:00 , Nov 4, 2013 |  BioCentury  |  Strategy

Teva blinks

With a deeply experienced CEO known for executing large, transformational deals, Teva Pharmaceutical Industries Ltd. had the chance to do something disruptive. But after the abrupt departure of President and CEO Jeremy Levin last Wednesday,...
07:00 , Sep 16, 2013 |  BC Week In Review  |  Company News

Adheron board of directors update

Adheron Therapeutics Inc. , Medford, Mass.   Business: Autoimmune   Appointed: Robert Baltera as executive chairman, formerly CEO of Amira Pharmaceuticals Inc. , which Bristol-Myers Squibb Co. acquired  ...
07:00 , Sep 16, 2013 |  BC Week In Review  |  Company News

Vital Therapies management update

Vital Therapies Inc. , San Diego, Calif.   Business: Hepatic   Transitioned: Aron Stern to chief administrative office and secretary from CFO; he is succeeded by Michael Swanson who also becomes treasurer, formerly CFO of...
08:00 , Jan 7, 2013 |  BioCentury  |  Finance

Novo's public moves

With small cap public biotechs living in a challenging financial environment, Novo A/S 's Novo Ventures group sees an opportunity to put its money to work. The group thinks depressed valuations mark an attractive entry...
08:00 , Nov 19, 2012 |  BioCentury  |  Strategy

Celgene's venture model

Although it has eschewed creating a corporate venture arm, Celgene Corp. has been an active investor in private biotechs for at least the last five years, tapping a network of scientists and VCs to identify...
07:00 , Oct 22, 2012 |  BC Week In Review  |  Company News

Celgene, PharmAria deal

Celgene will provide seed funding to PharmAria, a company founded earlier this year by alumni from now-acquired inflammation company Amira Pharmaceuticals Inc. Celgene will have an option to license certain R&D programs and an option...